艾迪注射液联合肝动脉灌注栓塞治疗原发性肝癌108例临床观察

摘要

目的:评价中药艾迪注射液联合肝动脉灌注栓塞治疗法治疗肝癌的疗效.方法:108例原发性肝癌患者随机分为治疗组和对照组,每组各54例.治疗组采用艾迪注射液60ml+0.9%氯化钠溶液500ml静脉点滴,d1-d21;静滴同时进行肝动脉灌注栓塞治疗,药物为羟基喜树碱(HCPT)10mg,氟尿嘧啶(5-FU)500mg,碘化油10ml,按Seldinger's技术要求,将药物注入肝脏肿瘤供养血管并行栓塞,28d为1周期.对照组54例单用肝动脉灌注栓塞治疗方案,同治疗组,2个周期后评价.结果:治疗组和对照组的有效率分别为80.4%和63.4%,中位生存期分别为8.34个月和8.21个月,6个月生存率分别为89.1%和84.8%,12个月生存率分别为63.4%和47.8%,24个月生存率分别为28.3%和17.4%.全组初治者6个月生存率83.1%,12个月生存率46.2%,24 个月生存率 18.5 %,复治者则分别为 96.2%,77.8%,33.3%.AFP疗后下降者治疗组29例有效率为69.4%,对照组21例,有效率为54.5%.结论:艾迪注射液能提高肝动脉灌注栓塞治疗疗效,改善生存质量,延长生存期.%Objective : To evaluate the efficacy of aidi injection combined with transcatheter artenal ehemo - embolization in patients with primary hepatic carcinoma.Methods : Patients with primary hepatic carcinoma( n = 108) were randomly divided into two groups.Patients( n = 54) in aidigroup were treated with intravenous aidi injection ( 60 ml in 500 ml 0.9％ NaCl) for 21 days( d 1-21 ) , and combined with transcatheter arterial chemoembolization ( HCPT 10 mg ,5 - FU 500 mg and iodinate oil 10 ml) for 28 days.The control patients( n = 46) were treated with transcatheter zuterial chemoembolization alone.After 2 circles of 28 - day treatment , the therapeutic effects were evaluated.Reasults : In aidi and control groups, the effective rates were 80.4％ and 63.0％ ; the median survival time was 8.34 and 8.21months; the mean survival time was 12.56 and 9.24months ; the half a year survival rate was 89.1％ and 84.8％ ; one year survival rate was 63.4％ and 47.8％ ; and two - year survival rate was 28.3％ and 17.4％ ,respectively.For the initial patients in the two groups , halfvear survival rate was 83.1％ ,one - year survival rate was 46.2％ , and No - year survival rate was 18.5％ ; for retreated patients , the corresponding rates were 96.2％ ,77.8％ and 33.3％ .The AFP decline rate was 69.4％ in 29 patients of aidi group,and 54.5％ in 21 patients of control group.Conclusion : Aidi injection can enhance the effect of transcatheter arterial chemoembolization,improve the quality of life and prolong the sruvival time in patients with primary hepatic carcinoma; the efficacy can be improved after repeated treatment.